Drug Approval | April 01, 2025
Morepen secures Loratadine approval for export to China
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
GE HealthCare’s Revolution Vibe CT enables more facilities to elevate patient care by offering advanced cardiac imaging technology
The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
The new combination therapy offers a dual mechanism of action for superior intraocular pressure control
Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy
The acquisition of MDxK further strengthens the Business Unit’s position in the molecular diagnostics market
Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
Subscribe To Our Newsletter & Stay Updated
